Inclusion Criteria:  ECOG performance status score: 0-1; Histopathologically documented local advanced or metastatic breast cancer ; Female of not childbearing potential must the related requirement; During or after the last systematic therapy before enrolment, disease progression occurred with clinical or radiographical documentation; Adequate organ functions as defined; Ability to understand and voluntarily agrees to participate by giving written informed consent for the study.  Exclusion Criteria:  For the case of symptomatic visceral metastasis, the investigators judged that it was not suitable to use relevant treatment; patients with active brain metastasis (without medical control or with clinical symptoms), cancerous meningitis, spinal cord compression, or patients with a history of primary tumors of the central nervous system ; History of clinically significant cardiovascular or cerebrovascular diseases; The subject has one of many factors affecting oral drugs; Active infection or fever with unknown cause > 38.5 °C; Active autoimmune diseases, History of immunodeficiency, including positive HIV serum test result and other acquired or congenital immunodeficiency diseases, or history of organ transplantation; Known history of allergy to study drug ingredients.